Posted by Michael Wonder on 29 Mar 2026
Enhertu followed by THP approved in China as the first and only HER2 directed ADC for the neo-adjuvant treatment of HER2 positive breast cancer
27 March 2026 - First approval of Daiichi Sankyo and AstraZeneca’s Enhertu globally in curative intent early breast cancer setting.
Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) has been approved in China for the neo-adjuvant treatment (before surgery) of adult patients with HER2 positive (immunohistochemistry 3+ or in situ hybridisation +) stage 2 (high risk) or stage 3 breast cancer.
